Compare RVMD & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | TCOM |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | Singapore |
| Employees | 883 | 43574 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 25.7B |
| IPO Year | N/A | N/A |
| Metric | RVMD | TCOM |
|---|---|---|
| Price | $187.35 | $42.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $140.84 | $78.75 |
| AVG Volume (30 Days) | 2.8M | ★ 3.8M |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $15.73 |
| Revenue Next Year | $533.02 | $13.00 |
| P/E Ratio | ★ N/A | $9.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.00 | $38.04 |
| 52 Week High | $193.83 | $79.00 |
| Indicator | RVMD | TCOM |
|---|---|---|
| Relative Strength Index (RSI) | 66.86 | 43.85 |
| Support Level | $93.39 | $38.04 |
| Resistance Level | N/A | $54.81 |
| Average True Range (ATR) | 7.33 | 1.29 |
| MACD | 0.42 | 0.16 |
| Stochastic Oscillator | 79.87 | 53.77 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.